Compare HNVR & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | ENLV |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 149.0M |
| IPO Year | 2022 | 2014 |
| Metric | HNVR | ENLV |
|---|---|---|
| Price | $25.04 | $4.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $24.50 | $20.00 |
| AVG Volume (30 Days) | 54.4K | ★ 280.7K |
| Earning Date | 04-27-2026 | 05-29-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.49 | N/A |
| Revenue Next Year | $8.61 | N/A |
| P/E Ratio | $99.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $0.43 |
| 52 Week High | $25.61 | $7.64 |
| Indicator | HNVR | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 62.24 | 57.84 |
| Support Level | $22.09 | $0.79 |
| Resistance Level | $25.61 | $7.64 |
| Average True Range (ATR) | 0.68 | 0.59 |
| MACD | 0.08 | -0.09 |
| Stochastic Oscillator | 75.82 | 50.64 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.